Results 121 to 130 of about 6,418,846 (364)

Tumor [PDF]

open access: yesOperative Neurosurgery, 2019
J Bradley, Elder   +19 more
openaire   +2 more sources

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

open access: yesMolecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski   +19 more
wiley   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Testicular tumors. A clinicopathological study [PDF]

open access: bronze, 1953
Frank J. Dixon, Robert A. Moore
openalex   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

Analysis of cell death-related genes to evaluate the prognostic and immunotherapeutic value in bladder cancer

open access: yesHeliyon
To enhance therapeutic approaches, we created a distinctive pattern utilizing the cell demise indicator (CDI) to predict the effectiveness of immunotherapy in individuals with bladder carcinoma (BLCA).
Mingde Gao   +6 more
doaj   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Granular-cell tumors of the stalk and posterior lobe of the pituitary gland [PDF]

open access: bronze, 1955
Sarah A. Luse, James W. Kernohan
openalex   +1 more source

TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.

open access: yesCancer Research, 2017
Taiwen Li   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy